若您需要咨询产品或有任何技术问题,请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系

StemSpan™ NK细胞分化添加物(100X)

用于淋系祖细胞向NK细胞分化的添加物

产品号 #(选择产品)

产品号 #09950_C

用于淋系祖细胞向NK细胞分化的添加物

专为您的实验方案打造的产品
要查看实验方案所需的所有配套产品,请参阅《实验方案与技术文档》

总览

StemSpan™ NK细胞分化添加物(100X)能支持淋系祖细胞向自然杀伤(NK)细胞分化。

该添加物是StemSpan™ NK细胞生成试剂盒或STEMdiff™ NK细胞分化试剂盒的组分之一,也可单独购买以方便您的使用。可使用该添加物将CD34+细胞在含StemSpan™淋系祖细胞扩增添加物(10X)的StemSpan™ SFEM II培养基中、在StemSpan™淋系分化包板材料(100X)包被的培养板上分化产生的淋系祖细胞进一步分化为NK细胞。

StemSpan™NK细胞分化添加物(100X)需与StemSpan™ SFEM II和UM729搭配使用以促进向CD56+ NK细胞的分化。

关于NK细胞生成方法的详细信息,请参阅技术手册。

该添加物是StemSpan™ NK细胞生成试剂盒或STEMdiff™ NK细胞分化试剂盒的组分之一,也可单独购买以方便您的使用。可使用该添加物将CD34+细胞在含StemSpan™淋系祖细胞扩增添加物(10X)的StemSpan™ SFEM II培养基中、在StemSpan™淋系分化包板材料(100X)包被的培养板上分化产生的淋系祖细胞进一步分化为NK细胞。

StemSpan™NK细胞分化添加物(100X)需与StemSpan™ SFEM II和UM729搭配使用以促进向CD56+ NK细胞的分化。

关于NK细胞生成方法的详细信息,请参阅技术手册。

该添加物是StemSpan™ NK细胞生成试剂盒或STEMdiff™ NK细胞分化试剂盒的组分之一,也可单独购买以方便您的使用。可使用该添加物将CD34+细胞在含StemSpan™淋系祖细胞扩增添加物(10X)的StemSpan™ SFEM II培养基中、在StemSpan™淋系分化包板材料(100X)包被的培养板上分化产生的淋系祖细胞进一步分化为NK细胞。

StemSpan™NK细胞分化添加物(100X)需与StemSpan™ SFEM II和UM729搭配使用以促进向CD56+ NK细胞的分化。

关于NK细胞生成方法的详细信息,请参阅技术手册。

该添加物是StemSpan™ NK细胞生成试剂盒或STEMdiff™ NK细胞分化试剂盒的组分之一,也可单独购买以方便您的使用。可使用该添加物将CD34+细胞在含StemSpan™淋系祖细胞扩增添加物(10X)的StemSpan™ SFEM II培养基中、在StemSpan™淋系分化包板材料(100X)包被的培养板上分化产生的淋系祖细胞进一步分化为NK细胞。

StemSpan™NK细胞分化添加物(100X)需与StemSpan™ SFEM II和UM729搭配使用以促进向CD56+ NK细胞的分化。

关于NK细胞生成方法的详细信息,请参阅技术手册。

亚型
添加剂
 
细胞类型
造血干/祖细胞,NK 细胞
 
种属

 
应用
分化
 
品牌
StemSpan
 
研究领域
癌症,免疫,干细胞生物学
 
制剂类别
无血清
 

实验数据

StemSpan™ NK procedure from seeding CB-derived CD34+ cells to harvesting of differentiated NK cells

Figure 1. StemSpan™ NK Cell Generation Protocol

CB-derived CD34+ cells are seeded on day 0. Medium should be topped up after 3 - 4 days of culture followed by two half-medium changes every 3 - 4 days. On day 14, cells at the lymphoid progenitor stage are harvested and reseeded for further differentiation into NK cells. Top-up and half-medium changes should be performed every 3 - 4 days after harvest and reseed, as indicated in the figure. Note: UM729 should only be added to the NK Cell Differentiation Medium, but not the Lymphoid Progenitor Expansion Medium.

Frequency and yield of CD56- and NKp46-expressing cells produced after culture of CD34+ HSPCs with the StemSpan™ NK Cell Generation Kit

Figure 2. Frequency and Yield of CD56+ NK Cells After 28 Days of Culture

CB-derived CD34+ cells (freshly isolated or frozen) were cultured with the StemSpan™ NK Cell Generation Kit for 28 days as described. Cells were harvested and analyzed for (A,B) CD56 and (A) NKp46 expression by flow cytometry. Dead cells were excluded by light scatter profile and viability staining. (B) The average frequency of viable CD56+ NK cells on day 28 was 77%, with ~9,000 CD56+ cells produced per input CB-derived CD34+ cell. Shown are means with 95% confidence intervals (n = 45: 23 freshly isolated and 22 frozen CD34+ cell samples). BM-derived CD34+ cells were also differentiated into NK cells using the StemSpan™ NK Cell Generation Kit. The yield of NK cells from BM HSPCs is typically lower than with CB, averaging ~75 per input CD34+ cell (n = 3, data not shown).

Flow cytometry plots showing cell surface marker expression on CD56+ NK cells after culture with the StemSpan™ NK Cell Generation Kit

Figure 3. Cell Surface Marker Expression on CD56+ NK Cells After 28 Days of Culture

CB-derived CD34+ cells were cultured with the StemSpan™ NK Cell Generation Kit for 28 days. The differentiated cells were harvested and analysed by flow cytometry for the expression of CD56, NKp44, NKp30, NKG2D, CD94, CD16, and KIR. Staining for KIR molecules was performed using a combination of two clones for the antibody, 180704 and HP-MA4, as each recognizes a distinct subset of KIR molecules.

Killing activity of NK cells toward K562 target cells compared to PB NK cells following culture with the StemSpan™ NK Cell Generation Kit

Figure 4. Cultured NK Cells Exhibit Cytotoxicity Toward K562 Cell Line

NK cells were generated from CB-derived CD34+ cells over 28 days using the protocol in Figure 1. On day 28, cells were harvested, stained for CD56, and viable CD56+ cells were counted. K562 cells were incubated with 8 μM calcein AM at 37°C for 1 hour and then washed twice. CD56+ NK cells were then combined with 10,000 of these calcein AM-labeled K562 target cells at an Effector:Target ratio of 5:1 in U-bottom 96-well plates and co-cultured at 37°C for 4 hours. Adult peripheral blood (PB) NK cells and monocytes isolated using EasySep™ were used as positive and negative controls, respectively. PB NK cells were cultured overnight with the NK Cell Differentiation Supplement and SFEM II, while PB monocytes were cultured overnight in SFEM II only. To detect spontaneous release, control wells containing only calcein AM-labeled K562 target cells were set up. The labeled K562 cells were treated with 1% Triton™ X-100 to measure maximum release. After incubation, plates were centrifuged at 500 x g for 5 minutes and 100 μL of supernatant was transferred to black plates and analyzed using a SpectraMax® microplate reader (excitation 485 nm/emission 530 nm). Results are expressed as % specific lysis: [(test release - spontaneous release) x 100] / (maximum release - spontaneous release). CB CD34+-derived NK cells show similar killing activity toward K562 target cells compared to PB NK cells. Shown are means ± SD (CB CD34+-derived NK cells: n = 18, PB NK cells and monocytes: n = 7).

产品说明书及文档

请在《产品说明书》中查找相关支持信息和使用说明,或浏览下方更多实验方案。

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
09950
Lot #
All
Language
English
Document Type
Technical Manual
Catalog #
09950
Lot #
All
Language
English
Document Type
Safety Data Sheet
Catalog #
09950
Lot #
All
Language
English

应用领域

本产品专为以下研究领域设计,适用于工作流程中的高亮阶段。探索这些工作流程,了解更多我们为各研究领域提供的其他配套产品。

更多信息

更多信息
种属 Human
配方类别 Serum-Free
质量保证:

产品仅供研究使用,不用于针对人或动物的诊断或治疗。 欲获悉更多关于STEMCELL的质控信息,请访问 STEMCELL.CN/COMPLIANCE.
Copyright © 2025 by STEMCELL Technologies. All rights reserved.